Literature DB >> 1533091

Lp(a) lipoprotein: relationship to cardiovascular disease risk factors, exercise, and estrogen.

R A Lobo1, M Notelovitz, L Bernstein, F Y Khan, R K Ross, W L Paul.   

Abstract

OBJECTIVE: Lp(a) lipoprotein is a distinct lipoprotein particle that recently has been found to be associated with cardiovascular disease. A study was conducted to assess the influence of cardiovascular disease risk factors on levels of Lp(a) and to evaluate the effects of age, exercise, and estrogen on these levels. STUDY
DESIGN: Two studies, a cross-sectional study of older men (n = 105) and women (n = 75) (mean age 76 years) and a prospective study of younger postmenopausal women (mean age 48 years), were carried out. Lp(a) and other lipoproteins were measured in the two studies and differences were sought by statistical analysis.
RESULTS: In the cross-sectional study, serum Lp(a) was similar in men and women and was not influenced by age. Lp(a) levels in men and women were higher when there was more than one cardiovascular disease risk factor present (p less than 0.028). We could not demonstrate such a relationship with other lipid and lipoprotein measurements. In the prospective study exercise alone had no influence on Lp(a) levels. Oral estrogen decreased Lp(a) levels marginally (p = 0.08). The decrease in Lp(a) with oral estrogen was associated with increases in triglycerides (p less than 0.01) and very-low-density lipoprotein (p less than 0.06).
CONCLUSIONS: These data confirm that elevated Lp(a) levels are an independent risk factor for cardiovascular disease. Lp(a) levels are primarily influenced by genetic factors and it appears estrogen may have a minor influence on its hepatic synthesis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1533091

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  11 in total

Review 1.  Hormones and heart disease: what we thought, what we have learned, what we still need to know.

Authors:  Marian C Limacher
Journal:  Trans Am Clin Climatol Assoc       Date:  2002

2.  Significant associations between lipoprotein(a) and corrected apolipoprotein B-100 levels in African-Americans.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Wei Zhang; Lars Berglund
Journal:  Atherosclerosis       Date:  2014-05-10       Impact factor: 5.162

Review 3.  Postmenopausal hormone replacement therapy, coronary heart disease and plasma lipoproteins.

Authors:  M Seed
Journal:  Drugs       Date:  1994       Impact factor: 9.546

Review 4.  Hormone replacement therapy in the aged. A state of the art review.

Authors:  S Jacobs; T C Hillard
Journal:  Drugs Aging       Date:  1996-03       Impact factor: 3.923

5.  Lipoprotein (a) does not participate in the early acute phase response to training or extreme physical activity and is unlikely to enhance any associated immediate cardiovascular risk.

Authors:  D J Byrne; I A Jagroop; H E Montgomery; M Thomas; D P Mikhailidis; N G Milton; A F Winder
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

Review 6.  Effects of exercise on lipoprotein(a).

Authors:  L T Mackinnon; L M Hubinger
Journal:  Sports Med       Date:  1999-07       Impact factor: 11.136

Review 7.  Estradiol and norgestimate: a review of their combined use as hormone replacement therapy in postmenopausal women.

Authors:  M P Curran; A J Wagstaff
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 8.  Lipoprotein (a): impact by ethnicity and environmental and medical conditions.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Lars Berglund
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

9.  Impact of hormone replacement therapy on postprandial lipoproteins and lipoprotein(a) in normolipidemic postmenopausal women.

Authors:  U Julius; H Fritsch; W Fritsch; E Rehak; K Fücker; W Leonhardt; M Hanefeld
Journal:  Clin Investig       Date:  1994-07

Review 10.  Ovarian sex steroids and atherosclerosis.

Authors:  M Riedel; W Rafflenbeul; P Lichtlen
Journal:  Clin Investig       Date:  1993-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.